ESPE Abstracts (2019) 92 P2-143

1Department of Paediatric Endocrinology, Great Ormond Street Hospital, London, United Kingdom. 2Department of Paediatric Metabolic medicine, Great Ormond Street Hospital, London, United Kingdom. 3Genetics and Genomics Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

Introduction: Tyrosinaemia type 1 (TT1) is a rare autosomal recessively inherited disorder of tyrosine metabolism leading to accumulation of tyrosine and its metabolites in liver, kidney and central nervous system. TT1 is a heterogeneous disorder with a broad spectrum of clinical manifestations. Hypoglycaemia is common, especially in the acute phase of the disease due to liver failure and reduced hepatic clearance of insulin. However, confirmed cases of hyperinsulinaemic hypoglycaemia have also been recently described.

Case: We describe the case of two siblings with TT1 who were born to consanguineous parents. Both siblings were found to be homozygous for pathogenic variant c.192G>Tp. (Gln64His) in fumarylacetoacetate hydrolase (FAH) gene which they inherited from their parents who were heterozygous carriers of the same mutation. The proband was a female child diagnosed with TT1 following elevated phenylalanine on newborn screening and liver failure. She was also found to be hypoglycaemic in the neonatal period. Hypoglycaemia screen confirmed the diagnosis of hyperinsulinaemic hypoglycaemia which was well controlled on a combination of diazoxide and chlorothiazide. Her treatment was discontinued after 8 months with normal blood glucose (BG) control and appropriate fasting duration since then.

Her brother was screened and diagnosed with TT1 at birth due to positive family history. He also manifested with neonatal hypoglycaemia. Diagnostic workup revealed detectable insulin at the time of hypoglycaemia and inability to mobilise ketones and fatty acids confirming the diagnosis of hyperinsulinaemic hypoglycaemia. Therefore, he was commenced on diazoxide and chlorothiazide which normalised his BG. His treatment was discontinued after 6 months with age-appropriate fast tolerance and no further hypoglycaemia off medication.

Conclusion: We describe two siblings with TT1 and acute liver dysfunction who had transient hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide (3mg/kg/day) and chlorothiazide (7mg/kg/day) and treatment was gradually withdrawn after 8 and 6 months, respectively.

Although histological abnormalities of the pancreas including beta cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1.

Volume 92

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.